VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
AGIOAgios Pharmaceuticals, Inc.
$34.16$2.0B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAGIOEarnings History

AGIO logoAgios Pharmaceuticals, Inc. (AGIO) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$423M
● Net Loss
TTM EPS (Diluted)
$-7.19
Per share, diluted
YoY EPS Growth
-161.2%
Declining
Net Margin
-764.0%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-873.9%
Gross Margin78.7%
Return on Equity-30.2%
Return on Assets-27.9%
Record Annual Net Income$1.60BFY2021
Record Quarterly EPS$26.95Q1 2021
Consecutive Profitable Years0years
Q1 2026
Net Income-$99M
EPS (Diluted)$-1.69
YoY Growth-161.2%Declining
QoQ Growth+8.3%Solid

Loading earnings history...

Agios Pharmaceuticals, Inc. (AGIO) Earnings Overview

As of June 22, 2026, Agios Pharmaceuticals, Inc. (AGIO) reported trailing twelve-month net income of -$423M, reflecting -161.2% year-over-year growth. The company earned $-7.19 per diluted share over the past four quarters, with a net profit margin of -764.0%.

Looking at the long-term picture, AGIO's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.60B in fiscal 2021.

Agios Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including IONS (-$327M net income, -40.4% margin), PTCT (-$187M net income, 39.4% margin), RARE (-$609M net income, -85.4% margin), AGIO has room to improve margins relative to the peer group. Compare AGIO vs IONS →

AGIO Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
AGIO logoAGIOCurrent
-$423M$-7.19-764.0%-30.2%-161.2%—
IONS logoIONS
-$327M$-1.98-40.4%-70.7%+21.7%
PTCT logoPTCT
-$187M$-2.2639.4%-+264.5%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
IMVT logoIMVT
-$506M$-2.48--64.8%-1.5%
Best in group
Lowest in group

AGIO Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$413M-161.3%-$472M$-7.12-764.0%-873.9%
2024$674M+291.4%-$426M$11.641845.9%-1166.5%
2023-$352M-51.9%-$391M$-6.33-1312.6%-1459.5%
2022-$232M-114.4%-$389M$-4.23-1627.8%-2732.1%
2021$1.60B+590.2%-$378M$-6.36--
2020-$327M+20.4%-$336M$-4.74--
2019-$411M-18.9%-$426M$-6.61-349.0%-361.6%
2018-$346M-10.0%-$362M$-6.03-366.6%-384.0%
2017-$315M-58.5%-$321M$-6.75-731.6%-745.8%
2016-$198M-68.6%-$201M$-5.07-284.0%-287.6%
2015-$118M-120.0%-$119M$-3.15-199.1%-200.8%
2014-$54M-35.8%-$54M$-1.59-81.9%-82.8%
2013-$39M-96.0%-$39M$-2.56-154.2%-152.2%
2012-$20M+15.2%-$23M$-0.86-80.1%-91.6%
2011-$24M--$17M$-1.01-108.6%-76.2%

Download Data

Export AGIO earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AGIO — Frequently Asked Questions

Quick answers to the most common questions about buying AGIO stock.

What is AGIO earnings per share (EPS)?

AGIO trailing twelve-month (TTM) diluted EPS is $-7.19, reflecting -161.2% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Agios Pharmaceuticals, Inc.'s net income?

Agios Pharmaceuticals, Inc. (AGIO) trailing twelve-month net income is $-423M as of 2025. Earnings declined -161.2% year-over-year.

Is AGIO profitable?

AGIO is not currently profitable on a TTM basis, reporting a net loss of $-423M. Net margin is -764.0%. Investors should monitor for a return to profitability.

What is AGIO's earnings growth rate?

AGIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are AGIO's profit margins?

Agios Pharmaceuticals, Inc. net profit margin is -764.0%, operating margin is -873.9%, and gross margin is +78.7%. Below-average margins reflect competitive or cost pressures. Return on Equity is -30.2%.

Is AGIO growing earnings?

AGIO earnings are declining — EPS fell -161.2% year-over-year. TTM net income dropped to $-423M. This contrasts with the 5-year CAGR of N/A.

What was AGIO's best earnings year?

Agios Pharmaceuticals, Inc.'s highest annual net income on record is $1.6B, achieved in fiscal year 2021. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were AGIO's earnings last quarter?

AGIO's most recent reported quarter was Q1 2026. Net income was $-99M with diluted EPS of $-1.69. For a full breakdown of all quarters, see the quarterly earnings table on this page.

AGIO Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view